The estimated Net Worth of Nicole Lambert is at least $7.96 Миллион dollars as of 27 March 2023. Ms Lambert owns over 6,433 units of Myriad Genetics stock worth over $6,320,498 and over the last 5 years she sold MYGN stock worth over $1,128,484. In addition, she makes $507,506 as Chief Operating Officer at Myriad Genetics.
Ms has made over 7 trades of the Myriad Genetics stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 6,433 units of MYGN stock worth $151,047 on 27 March 2023.
The largest trade she's ever made was selling 13,184 units of Myriad Genetics stock on 2 March 2023 worth over $299,804. On average, Ms trades about 1,231 units every 33 days since 2019. As of 27 March 2023 she still owns at least 240,506 units of Myriad Genetics stock.
You can see the complete history of Ms Lambert stock trades at the bottom of the page.
Nicole Lambert is the Chief Operating Officer at Myriad Genetics.
As the Chief Operating Officer of Myriad Genetics, the total compensation of Ms Lambert at Myriad Genetics is $507,506. There are 8 executives at Myriad Genetics getting paid more, with R. Bryan Riggsbee having the highest compensation of $3,138,980.
Ms Lambert is 47, she's been the Chief Operating Officer of Myriad Genetics since . There are 21 older and 4 younger executives at Myriad Genetics. The oldest executive at Myriad Genetics, Inc. is Walter Gilbert, 87, who is the Independent Vice Chairman of the Board.
Nicole's mailing address filed with the SEC is 320, Wakara Way, U of U Research Park, Salt Lake City, Salt Lake County, Utah, 84108, United States.
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum и Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: